Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 10/2004

01-08-2004 | Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation

Authors: Dr Christine E. Staatz, Susan E. Tett

Published in: Clinical Pharmacokinetics | Issue 10/2004

Login to get access

Abstract

The aim of this review is to analyse critically the recent literature on the clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplant recipients.
Dosage and target concentration recommendations for tacrolimus vary from centre to centre, and large pharmacokinetic variability makes it difficult to predict what concentration will be achieved with a particular dose or dosage change. Therapeutic ranges have not been based on statistical approaches. The majority of pharmacokinetic studies have involved intense blood sampling in small homogeneous groups in the immediate post-transplant period. Most have used nonspecific immunoassays and provide little information on pharmacokinetic variability. Demographic investigations seeking correlations between pharmacokinetic parameters and patient factors have generally looked at one covariate at a time and have involved small patient numbers. Factors reported to influence the pharmacokinetics of tacrolimus include the patient group studied, hepatic dysfunction, hepatitis C status, time after transplantation, patient age, donor liver characteristics, recipient race, haematocrit and albumin concentrations, diurnal rhythm, food administration, corticosteroid dosage, diarrhoea and cytochrome P450 (CYP) isoenzyme and P-glycoprotein expression. Population analyses are adding to our understanding of the pharmacokinetics of tacrolimus, but such investigations are still in their infancy. A significant proportion of model variability remains unexplained. Population modelling and Bayesian forecasting may be improved if CYP isoenzymes and/or P-glycoprotein expression could be considered as covariates.
Reports have been conflicting as to whether low tacrolimus trough concentrations are related to rejection. Several studies have demonstrated a correlation between high trough concentrations and toxicity, particularly nephrotoxicity. The best predictor of pharmacological effect may be drug concentrations in the transplanted organ itself. Researchers have started to question current reliance on trough measurement during therapeutic drug monitoring, with instances of toxicity and rejection occurring when trough concentrations are within ‘acceptable’ ranges. The correlation between blood concentration and drug exposure can be improved by use of non-trough timepoints. However, controversy exists as to whether this will provide any great benefit, given the added complexity in monitoring. Investigators are now attempting to quantify the pharmacological effects of tacrolimus on immune cells through assays that measure in vivo calcineurin inhibition and markers of immunosuppression such as cytokine concentration. To date, no studies have correlated pharmacodynamic marker assay results with immunosuppressive efficacy, as determined by allograft outcome, or investigated the relationship between calcineurin inhibition and drug adverse effects. Little is known about the magnitude of the pharmacodynamic variability of tacrolimus.
Literature
1.
Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59(2): 323–89PubMedCrossRef
2.
Pham SM, Kormos RL, Kawai A, et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. Transplant Proc 1996; 28(2): 1002–4PubMed
3.
De Bonis M, Reynolds L, Barros J, et al. Tacrolimus as a rescue immunosuppressant after heart transplantation. Eur J Cardiothorac Surg 2001; 19(5): 690–5PubMedCrossRef
4.
Crespo-Leiro MG, Paniagua MJ, Mosquera I, et al. Replacement of cyclosporine by tacrolimus for immunosuppression in heart transplant patients: safety and efficacy. Transplant Proc 2002; 34(1): 113–4PubMedCrossRef
5.
Swenson JM, Fricker FJ, Armitage JM. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506. J Am Coll Cardiol 1995; 25(5): 1183–8PubMedCrossRef
6.
Reyes J, Mazariegos GV, Bond GM, et al. Pediatric intestinal transplantation: historical notes, principles and controversies. Pediatr Transplant 2002; 6(3): 193–207PubMedCrossRef
7.
Kato T, Ruiz P, Thompson JF, et al. Intestinal and multivisceral transplantation. World J Surg 2002; 26(2): 226–37PubMedCrossRef
8.
Jindal RM, Dubernard JM. Towards a specific immunosuppression for pancreas and islet grafts. Clin Transplant 2000; 14(3): 242–5PubMedCrossRef
9.
Stratta RJ. Optimal immunosuppression in pancreas transplantation. Transplant Proc 1999; 31 (1–2): 619–21PubMedCrossRef
10.
Stratta RJ, Taylor RJ, Castaldo P, et al. FK 506 induction and rescue therapy in pancreas transplant recipients. Transplant Proc 1996; 28(2): 991–2PubMed
11.
Gruessner RW. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Clin Transplant 1997; 11(4): 299–312PubMed
12.
Jordan ML, Shapiro R, Gritsch HA, et al. Long-term results of pancreas transplantation under tacrolimus immunosuppression. Transplantation 1999; 67(2): 266–72PubMedCrossRef
13.
Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92(7): 2303–14PubMed
14.
Fay JW, Wingard JR, Antin JH, et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 1996; 87(8): 3514–9PubMed
15.
Jacobson P, Uberti J, Davis W, et al. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22(3): 217–25PubMedCrossRef
16.
Lee TJ, Kennedy LA. Tacrolimus: an alternative for graft-versus-host disease prevention. Ann Pharmacother 2000; 34(3): 377–81PubMedCrossRef
17.
Yanik G, Levine JE, Ratanatharathorn V, et al. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26(2): 161–7PubMedCrossRef
18.
Horning NR, Lynch JP, Sundaresan SR, et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant 1998; 17(8): 761–7PubMed
19.
Kur F, Reichenspurner H, Meiser BM, et al. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. Thorac Cardiovasc Surg 1999; 47(3): 174–8PubMedCrossRef
20.
Lipson DA, Palevsky HI, Kotloff RM, et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. Transplant Proc 1998; 30(4): 1505–7PubMedCrossRef
21.
Reichenspurner H, Kur F, Treede H, et al. Optimization of the immunosuppressive protocol after lung transplantation. Transplantation 1999; 68(1): 67–71PubMedCrossRef
22.
Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001; 20(5): 511–7PubMedCrossRef
23.
Busuttil RW, Holt CD. Tacrolimus is superior to cyclosporine in liver transplantation. Transplant Proc 1998; 30(5): 2174–8PubMedCrossRef
24.
Cao S, Cox KL, Berquist W, et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. Pediatr Transplant 1999; 3(1): 22–6PubMedCrossRef
25.
McDiarmid SV. The use of tacrolimus in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 1998; 26(1): 90–102PubMedCrossRef
26.
Reyes J, Jain A, Mazariegos G, et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 2000; 69(12): 2573–80PubMedCrossRef
27.
Berloco P, Rossi M, Pretagostini R, et al. Tacrolimus as cornerstone immunosuppressant in kidney transplantation. Transplant Proc 2001; 33(1–2): 994–6PubMedCrossRef
28.
Laskow DA, Neylan JF, Shapiro RS, et al. The role of tacrolimus in adult kidney transplantation: a review. Clin Transplant 1998; 12(6): 489–503PubMed
29.
Shapiro R. Tacrolimus in solid organ transplantation: an update. Transplant Proc 1999; 31(6): 2203–5PubMedCrossRef
30.
Shapiro R. Tacrolimus in pediatric renal transplantation: a review. Pediatr Transplant 1998; 2(4): 270–6PubMed
31.
Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29(6): 404–30PubMedCrossRef
32.
Trull AK. Therapeutic monitoring of tacrolimus. Ann Clin Biochem 1998; 35 (Pt 2): 167–80PubMed
33.
Taylor DO, Barr ML, Meiser BM, et al. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. J Heart Lung Transplant 2001; 20(7): 734–8PubMedCrossRef
34.
Walker S, Habib S, Rose M, et al. Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. Transplant Proc 1998; 30(4): 1519–20PubMedCrossRef
35.
36.
van Hooff JP, Boots JM, van Duijnhoven EM, et al. Dosing and management guidelines for tacrolimus in renal transplant patients. Transplant Proc 1999; 31(7A): 54–7SCrossRef
37.
Busuttil RW, Klintmalm GB, Lake JR, et al. General guidelines for the use of tacrolimus in adult liver transplant patients. Transplantation 1996; 61(5): 845–7PubMedCrossRef
38.
Garrity ER, Hertz MI, Trulock EP, et al. Suggested guidelines for the use of tacrolimus in lung-transplant recipients. J Heart Lung Transplant 1999; 18(3): 175–6PubMedCrossRef
39.
Gruessner RW, Bartlett ST, Burke GW, et al. Suggested guidelines for the use of tacrolimus in pancreas/kidney transplantation. Clin Transplant 1998; 12(3): 260–2PubMed
40.
Ellis D. Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. Pediatr Nephrol 1995; 9(4): 487–94PubMedCrossRef
41.
Esquivel CO, So SK, McDiarmid SV, et al. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. Transplantation 1996; 61(5): 847–8PubMedCrossRef
42.
van Mourik ID, Kelly DA. Immunosuppressive drugs in paediatric liver transplantation. Paediatr Drugs 2001; 3(1): 43–60PubMedCrossRef
43.
Furlan V, Debray D, Fourre C, et al. Conversion from cyclosporin A to tacrolimus in pediatric liver transplantation. Pediatr Transplant 2000; 4(3): 207–10PubMedCrossRef
44.
Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38 (6 Suppl. 6): S25–35PubMedCrossRef
45.
Kokado Y, Takahara S, Kyo M, et al. Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation. Transpl Int 1998; 11 Suppl. 1: S60–4PubMed
46.
Hasegawa A, Takahashi K, Ito K, et al. Optimal use of tacrolimus in living donor renal transplantation in children. Transplant Proc 2002; 34(5): 1939–41PubMedCrossRef
47.
Wallemacq PE, Furlan V, Moller A, et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet 1998; 23(3): 367–70PubMedCrossRef
48.
Gruber SA, Hewitt JM, Sorenson AL, et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol 1994; 34(8): 859–64PubMed
49.
Jain A, Venkataramanan R, Todo S, et al. Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. Transplant Proc 1992; 24(3): 1181–2PubMed
50.
Fitzsimmons WE, Bekersky I, Dressler D, et al. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 1998; 30(4): 1359–64PubMedCrossRef
51.
Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65(4): 515–23PubMedCrossRef
52.
Neylan JF. Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. Transplant Proc 1998; 30(4): 1355–8PubMedCrossRef
53.
Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69(1): 24–31PubMedCrossRef
54.
Felipe CR, Garcia C, Moreira S, et al. Choosing the right dose of new immunosuppressive drugs for new populations: importance of pharmacokinetic studies. Transplant Proc 2001; 33(1–2): 1095–6PubMedCrossRef
55.
van Duijnhoven E, Christiaans M, Schafer A, et al. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 1998; 30(4): 1266–7PubMedCrossRef
56.
Hu RH, Lee PH, Tsai MK. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. Transplant Proc 2000; 32(7): 1689–92PubMedCrossRef
57.
Mekki Q, Lee CC, Carrier S, et al. The effect of food on oral bioavailability of tacrolimus (FK506) in liver transplant patients [abstract]. Clin Pharmacol Ther 1993; 53(2): 229
58.
Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5mg single oral doses to healthy human subjects. J Clin Pharmacol 2001; 41(2): 176–82PubMedCrossRef
59.
Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5mg tacrolimus dose. J Clin Pharmacol 2001; 41(3): 289–97PubMedCrossRef
60.
Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 1991; 23(6): 2736–40PubMed
61.
Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57(3): 281–90PubMedCrossRef
62.
Tuteja S, Alloway RR, Johnson JA, et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001; 71(9): 1303–7PubMedCrossRef
63.
Benet LZ. Impact of intraindividual variability of drugs on therapeutic outcomes: lessons from outside transplantation. Transplant Proc 1998; 30(5): 1650–1PubMedCrossRef
64.
Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40(3): 159–68PubMedCrossRef
65.
Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23(12): 1315–24PubMed
66.
Lampen A, Christians U, Gonschior AK, et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol 1996; 117(8): 1730–4PubMedCrossRef
67.
Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283(3): 1552–62PubMed
68.
Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87(11): 1322–30PubMedCrossRef
69.
de Waziers I, Cugnenc PH, Yang CS, et al. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253(1): 387–94PubMed
70.
Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999; 62(1-2): 25–31PubMedCrossRef
71.
Gan LS, Moseley MA, Khosla B, et al. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 1996; 24(3): 344–9PubMed
72.
Lo A, Burckart G. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999; 39: 995–1005PubMedCrossRef
73.
Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987; 84(1): 265–9PubMedCrossRef
74.
Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62(3): 248–60PubMedCrossRef
75.
Venkataramanan R, Jain A, Warty VW, et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc 1991; 23(1 Pt 2): 931–3PubMed
76.
Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990; 22(1): 57–9PubMed
77.
Bottiger Y, Undre N, Sawe J, et al. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. Transplant Proc 2002; 34(5): 1544–5PubMedCrossRef
78.
Murray M, Grogan TA, Lever J, et al. Comparison of tacrolimus absorption in transplant patients receiving continuous versus interrupted enteral nutritional feeding. Ann Pharmacother 1998; 32(6): 633–6PubMedCrossRef
79.
Warty VS, Venkataramanan R, Zendehrouh P, et al. Practical aspects of FK 506 analysis (Pittsburgh experience). Transplant Proc 1991; 23(6): 2730–1PubMed
80.
Jusko WJ, D’Ambrosio R. Monitoring FK 506 concentrations in plasma and whole blood. Transplant Proc 1991; 23(6): 2732–5PubMed
81.
Beysens AJ, Wijnen RM, Beuman GH, et al. FK 506: monitoring in plasma or in whole blood? Transplant Proc 1991; 23(6): 2745–7PubMed
82.
Jusko WJ. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Ther Drug Monit 1995; 17(6): 596–601PubMedCrossRef
83.
Ericzon BG, Ekqvist B, Groth CG, et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. Transplant Proc 1991; 23(6): 2775–6PubMed
84.
Machida M, Takahara S, Ishibashi M, et al. Effect of temperature and hematocrit on plasma concentration of FK 506. Transplant Proc 1991; 23(6): 2753–4PubMed
85.
Nagase K, Iwasaki K, Nozaki K, et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 1994; 46(2): 113–7PubMedCrossRef
86.
Kay JE, Sampare-Kwateng E, Geraghty F, et al. Uptake of FK 506 by lymphocytes and erythrocytes. Transplant Proc 1991; 23(6): 2760–2PubMed
87.
Kobayashi M, Tamura K, Katayama N, et al. FK 506 assay past and present-characteristics of FK 506 ELISA. Transplant Proc 1991; 23(6): 2725–9PubMed
88.
Piekoszewski W, Chow FS, Jusko WJ. Disposition of tacrolimus (FK 506) in rabbits: role of red blood cell binding in hepatic clearance. Drug Metab Dispos 1993; 21(4): 690–8PubMed
89.
Jain A, Venkataramanan R, Lever J, et al. FK506 and pregnancy in liver transplant patients. Transplantation 1993; 56(6): 1588–9PubMed
90.
Jain A, Venkataramanan R, Fung JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997; 64(4): 559–65PubMedCrossRef
91.
Jain AB, Fung JJ, Tzakis AG, et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant Proc 1991; 23(6): 2763–6PubMed
92.
Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 2001; 40(4): 283–95PubMedCrossRef
93.
Moller A, Iwasaki K, Kawamura A, et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 1999; 27(6): 633–6PubMed
94.
Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 1996; 24(5): 461–73PubMed
95.
de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37(6): 485–505PubMedCrossRef
96.
Karanam BV, Vincent SH, Newton DJ, et al. FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug Metab Dispos 1994; 22(5): 811–4PubMed
97.
Lemoine A, Azoulay D, Gries JM, et al. Relationship between graft cytochrome P-450 3A content and early morbidity after liver transplantation. Transplantation 1993; 56(6): 1410–4PubMedCrossRef
98.
Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20(5): 753–61PubMed
99.
Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996; 24(5): 475–90PubMed
100.
Gellner KR, Eiselt R, Hustert E, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11(2): 111–21PubMedCrossRef
101.
Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54(10): 1271–94PubMedCrossRef
102.
Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38(2): 207–13PubMed
103.
Schuetz JD, Molowa DT, Guzelian PS. Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. Arch Biochem Biophys 1989; 274(2): 355–65PubMedCrossRef
104.
Tateishi T, Watanabe M, Moriya H, et al. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999; 57(8): 935–9PubMedCrossRef
105.
Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27(4): 383–91PubMedCrossRef
106.
Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62(1): 162–72PubMedCrossRef
107.
Domanski TL, Finta C, Halpert JR, et al. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59(2): 386–92PubMed
108.
Westlind A, Malmebo S, Johansson I, et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281(5): 1349–55PubMedCrossRef
109.
Christians U, Braun F, Kosian N, et al. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. Transplant Proc 1991; 23(6): 2741–4PubMed
110.
Christians U, Kruse C, Kownatzki R, et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. Transplant Proc 1991; 23(1 Pt 2): 940–1PubMed
111.
Christians U, Radeke HH, Kownatzki R, et al. Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. Clin Biochem 1991; 24(3): 271–5PubMedCrossRef
112.
Christians U, Braun F, Schmidt M, et al. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. Clin Chem 1992; 38(10): 2025–32PubMed
113.
Iwasaki K, Shiraga T, Matsuda H, et al. Further metabolism of FK506 (tacrolimus): identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 1995; 23(1): 28–34PubMed
114.
Alak AM, Moy S. Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. Transplant Proc 1997; 29(5): 2487–90PubMedCrossRef
115.
Gonschior AK, Christians U, Winkler M, et al. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem 1996; 42(9): 1426–32PubMed
116.
Venkataramanan R, Jain AK, Lever J, et al. Pharmacokinetics of tacrolimus (Tac) in transplant patients [abstract]. Ther Drug Monit 1995; 17(4): 416CrossRef
117.
Gonschior AK, Christians U, Braun F, et al. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). Br J Clin Pharmacol 1994; 38(6): 567–71PubMedCrossRef
118.
Iwasaki K, Shiraga T, Nagase K, et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos 1993; 21(6): 971–7PubMed
119.
Boswell GW, Bekersky I, Fay J, et al. Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant 1998; 21(1): 23–8PubMedCrossRef
120.
Mekki QA, Piscitelli D, Fitzsimmons WE. Pharmacokinetics of tacrolimus in bone marrow transplant patients [abstract]. Clin Pharmacol Ther 1993; 55(2): 149
121.
Bekersky I, Dressler D, Alak A, et al. Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. J Clin Pharmacol 2001; 41(6): 628–35PubMedCrossRef
122.
Hebert MF, Fisher RM, Marsh CL, et al. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39(1): 91–6PubMedCrossRef
123.
Steinmuller DR. FK506 and organ transplantation. Austin (TX): Medical Intelligence Unit, RG Landers Co, 1994: 1–111
124.
Venkataramanan R, Jain A, Lever J, et al. High dose tacrolimus requirements in transplant patients [abstract]. Pharm Res 1994; 7: 329–33
125.
Satoh S, Tada H, Tachiki Y, et al. Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration. Int J Urol 2001; 8(7): 353–8PubMedCrossRef
126.
Aweeka FT, Benet LZ, Gambertoglio JG, et al. Comparitive pharmacokinetics of orally (PO) and intravenously (IV) administered tacrolimus (FK506) in pre- and post-kidney transplant recipients [abstract]. Clin Pharmacol Ther 1993; 53(2): 151
127.
Lee CC, Hewitt JM, Aweeka FT, et al. Pharmacokinetics of tacrolimus (FK506) prior to kidney transplantation [abstract]. Clin Pharmacol Ther 1993; 53(2): 238
128.
Saito K, Suwa M, Nakagawa Y, et al. Study of pharmacokinetic parameters of tacrolimus by different oral administration periods in renal transplantation. Transplant Proc 2002; 34(5): 1726–9PubMedCrossRef
129.
Mekki QA, Lee CC, Aweeka FT, et al. Pharmacokinetics of tacrolimus (FK506) in kidney transplant patients [abstract]. Clin Pharmacol Ther 1993; 53(2): 238
130.
Tuteja S, Alloway RR, Johnson JA, et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001; 71(9): 1303–7PubMedCrossRef
131.
Lee CC, Jusko WJ, Shaefer MS, et al. Pharmacokinetics of tacrolimus (FK506) in liver transplant patients [abstract]. Clin Pharmacol Ther 1993; 53(2): 181
132.
Jain A, Venkataramanan R, Lever J, et al. FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. Transplant Proc 1994; 26(3): 1609–10PubMed
133.
Venkataramanan R, Jain A, Cadoff E, et al. Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc 1990; 22(1): 52–6PubMed
134.
Shishido S, Asanuma H, Tajima E, et al. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 2001; 33(1–2): 1066–8PubMedCrossRef
135.
Webb N, Stevenson P, Lewis M, et al. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Transplant Proc 2002; 34(5): 1948–50PubMedCrossRef
136.
Sewing KF. Pharmacokinetics, dosing principles, and blood level monitoring of FK506. Transplant Proc 1994; 26(6): 3267–9PubMed
137.
Regazzi MB, Rinaldi M, Molinaro M, et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Ther Drug Monit 1999; 21(1): 2–7PubMedCrossRef
138.
Molinaro M, Regazzi MB, Pasquino S, et al. Pharmacokinetics of tacrolimus during the early phase after heart transplantation. Transplant Proc 2001; 33(3): 2386–9PubMedCrossRef
139.
Undre N, Stevenson P. Pharmacokinetics of tacrolimus in heart transplantation. Transplant Proc 2002; 34(5): 1836–8PubMedCrossRef
140.
Mehta P, Beltz S, Kedar A, et al. Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. Bone Marrow Transplant 1999; 24(12): 1323–7PubMedCrossRef
141.
Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995; 17(6): 606–14PubMedCrossRef
142.
Kuzuya T, Ogura Y, Motegi Y, et al. Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay. Ther Drug Monit 2002; 24(4): 507–11PubMedCrossRef
143.
McMasters P, Mirza DF, Ismail T, et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995; 17(6): 602–5CrossRef
144.
Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41(11): 813–51PubMedCrossRef
145.
Jain AB, Abu-Elmagd K, Abdallah H, et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol 1993; 33(7): 606–11PubMed
146.
Abu-Elmagd K, Fung JJ, Alessiani M, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991; 52(1): 71–7PubMedCrossRef
147.
Abu-Elmagd KM, Fung JJ, Alessiani M, et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc 1991; 23(6): 2771–4PubMed
148.
Pou L, Brunet M, Andres I, et al. Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. Transpl Int 1998; 11 Suppl. 1: S270–1PubMed
149.
Manzanares C, Moreno M, Castellanos F, et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. Transplant Proc 1998; 30(4): 1264–5PubMedCrossRef
150.
van den Berg AP, Haagsma EB, Gouw AS, et al. Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. Transplant Proc 2001; 33(1–2): 1467PubMedCrossRef
151.
Moreno M, Manzanares C, Castellano F, et al. Monitoring of tacrolimus as rescue therapy in pediatric liver transplantation. Ther Drug Monit 1998; 20(4): 376–9PubMedCrossRef
152.
Horina JH, Wirnsberger GH, Kenner L, et al. Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. Transplantation 1993; 56(5): 1091–4PubMedCrossRef
153.
Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc 1998; 30(4): 1261–3PubMedCrossRef
154.
Christiaans M, van Duijnhoven E, Beysens T, et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc 1998; 30(4): 1271–3PubMedCrossRef
155.
McDiarmid SV, Colonna JO, Shaked A, et al. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation 1993; 55(6): 1328–32PubMedCrossRef
156.
Satomura K, Ozaki N, Okajima H, et al. Pharmacokinetics of FK 506 in living-related liver transplantation. Transplant Proc 1996; 28(2): 1005PubMed
157.
Yasuhara M, Hashida T, Toraguchi M, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 1995; 27(1): 1108–10PubMed
158.
Uemoto S, Tanaka K, Honda K, et al. Experience with FK506 in living-related liver transplantation. Transplantation 1993; 55(2): 288–92PubMedCrossRef
159.
Cacciarelli TV, Esquivel CO, Cox KL, et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996; 61(8): 1188–92PubMedCrossRef
160.
MacFarlane GD, Venkataramanan R, McDiarmid SV, et al. Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients. Pediatr Transplant 2001; 5(2): 119–24PubMedCrossRef
161.
Przepiorka D, Blamble D, Hilsenbeck S, et al. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 2000; 26(6): 601–5PubMedCrossRef
162.
Mittal N, Thompson JF, Kato T, et al. Tacrolimus and diarrhea: pathogenesis of altered metabolism. Pediatr Transplant 2001; 5(2): 75–9PubMedCrossRef
163.
Teperman LW, Morgan GR, Diflo T, et al. Tacrolimus dose is donor age dependent [abstract]. 24th Annual Scientific Meeting of the American Society of Transplant Surgeons; 1998 May 13–15; Chicago
164.
Taber DJ, Dupuis RE, Fann AL, et al. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver Transpl 2002; 8(3): 219–23PubMedCrossRef
165.
Trotter JF, Stolpman N, Wachs M, et al. Living donor liver transplant recipients achieve relatively higher immuno-suppressant blood levels than cadaveric recipients. Liver Transpl 2002; 8(3): 212–8PubMedCrossRef
166.
Troisi R, Militerno G, Hoste E, et al. Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults? Transplant Proc 2002; 34(5): 1531–2PubMedCrossRef
167.
Harihara Y, Sano K, Makuuchi M, et al. Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation. Transplant Proc 2000; 32(7): 2166–7PubMedCrossRef
168.
Sugawara Y, Makuuchi M, Kaneko J, et al. Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant 2002; 16(2): 102–6PubMedCrossRef
169.
Nakazawa Y, Chisuwa H, Ikegami T, et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. Transplantation 1998; 66(8): 1089–93PubMedCrossRef
170.
Felipe CR, Silva HT, Machado PG, et al. The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin Transplant 2002; 16(4): 262–72PubMedCrossRef
171.
Uber PA, Mehra MR, Scott RL, et al. Ethnic disparities in the pharmacologic characteristics of tacrolimus in heart transplantation. Transplant Proc 2001; 33(1–2): 1581–2PubMedCrossRef
172.
Huang ML, Venkataramanan R, Burckart GJ, et al. Drug-binding proteins in liver transplant patients. J Clin Pharmacol 1988; 28(6): 505–6PubMed
173.
Min DI, Chen HY, Fabrega A, et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation 1996; 62(8): 1190–2PubMedCrossRef
174.
Kimikawa M, Kamoya K, Toma H, et al. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant 2001; 15(5): 324–9PubMedCrossRef
175.
van Duijnhoven E, Christiaans M, Boots J, et al. Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients. Transplant Proc 2002; 34(5): 1723–5PubMedCrossRef
176.
Eades SK, Boineau FG, Christensen ML. Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea. Pediatr Transplant 2000; 4(1): 63–6PubMedCrossRef
177.
Hochleitner BW, Bosmuller C, Nehoda H, et al. Increased tacrolimus levels during diarrhea. Transpl Int 2001; 14(4): 230–3PubMedCrossRef
178.
Matsui A, Arakawa Y, Momoya T, et al. Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. Acta Paediatr Jpn 1996; 38(6): 699–701PubMedCrossRef
179.
Fruhwirth M, Fischer H, Simma B, et al. Rotavirus infection as cause of tacrolimus elevation in solid-organ- transplanted children. Pediatr Transplant 2001; 5(2): 88–92PubMedCrossRef
180.
Fruhwirth M, Fischer H, Simma B, et al. Elevated tacrolimus trough levels in association with mycophenolate mofetil-induced diarrhea: a case report. Pediatr Transplant 2001; 5(2): 132–4PubMedCrossRef
181.
Zylber-Katz E, Granot E. Abrupt increase of tacrolimus blood levels during an episode of Shigella infection in a child after liver transplantation. Ther Drug Monit 2001; 23(6): 647–9PubMedCrossRef
182.
Itagaki F, Hori T, Tomita T, et al. Effect of ascites on tacrolimus disposition in a liver transplant recipient. Ther Drug Monit 2001; 23(6): 644–6PubMedCrossRef
183.
Novelli M, Muiesan P, Mieli-Vergani G, et al. Oral absorption of tacrolimus in children with intestinal failure due to short or absent small bowel. Transpl Int 1999; 12(6): 463–5PubMedCrossRef
184.
Hasegawa T, Nara K, Kimura T, et al. Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. Pediatr Transplant 2001; 5(3): 204–9PubMedCrossRef
185.
Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3(4): 477–83PubMedCrossRef
186.
MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4(6): 914–9PubMedCrossRef
187.
McPhee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74(11): 1486–9CrossRef
188.
Hesselink DA, van Schaik RHN, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors and cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74(3): 245–54PubMedCrossRef
189.
de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P4503A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37(6): 485–505PubMedCrossRef
190.
Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27(4): 383–91PubMedCrossRef
191.
Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11(9): 773–9PubMedCrossRef
192.
Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54(10): 1271–94PubMedCrossRef
193.
Amirimani B, Walker AH, Weber BL, et al. Response: modification of clinical presentation of prostrate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999; 91: 1588–90PubMedCrossRef
194.
Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72(2): 209–19PubMedCrossRef
195.
Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13(2): 89–95PubMedCrossRef
196.
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97(7): 3473–8PubMedCrossRef
197.
Lin JH, Yamazaki M. Role of p-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42(1): 59–98PubMedCrossRef
198.
Fredericks S, Holt DW, MacPhee IAM. The pharmacogenetics of immunosuppression for organ transplantation. Am J Pharmacogenomics 2003; 3(5): 291–301PubMedCrossRef
199.
Kaplan B, Lown K, Craig R, et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 1999; 67(2): 333–5PubMedCrossRef
200.
Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69(5): 308–16PubMedCrossRef
201.
Masuda S, Uemoto S, Hashida T, et al. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000; 68(1): 98–103PubMedCrossRef
202.
Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27(2–3): 201–14PubMedCrossRef
203.
Tett SE, Holford NHG, McLachlan AJ. Population pharmacokinetics and pharmacodynamics: an underutilized resource. Drug Inf J 1998; 32: 693–710CrossRef
204.
Minto C, Schnider T. Expanding clinical applications of population pharmacodynamic modelling. Br J Clin Pharmacol 1998; 46(4): 321–33PubMedCrossRef
205.
Williams PJ, Ette EI. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration’s ‘Guidance for Industry: population pharmacokinetic’. Clin Pharmacokinet 2000; 39(6): 385–95PubMedCrossRef
206.
Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5(5): 445–79PubMed
207.
Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22(6): 447–67PubMedCrossRef
208.
Sam WJ, Aw M, Quak SH, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 2000; 50(6): 531–41PubMedCrossRef
209.
Garcia Sanchez MJ, Manzanares C, Santos-Buelga D, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 2001; 40(1): 63–71PubMedCrossRef
210.
Staatz CE, Taylor PJ, Lynch SV, et al. Population pharmacokinetics of tacrolimus in children who receive cut- down or full liver transplants. Transplantation 2001; 72(6): 1056–61PubMedCrossRef
211.
Mekki QA, Lee CC. Population pharmacokinetics of tacrolimus (FK506) in liver transplant patients [abstract]. Clin Pharmacol Ther 1994; 55(2): 162
212.
213.
Macchi-Andanson M, Charpiat B, Jelliffe RW, et al. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 2001; 23(2): 129–33PubMedCrossRef
214.
Staatz CE, Willis C, Taylor PJ, et al. Towards better outcomes with tacrolimus therapy: population pharmacokinetics and individualised dosage prediction in adult liver transplantation. Liver Transpl 2003; 9: 130–7PubMedCrossRef
215.
Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 2001; 57(6–7): 479–84PubMed
216.
Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72(6): 660–9PubMedCrossRef
217.
Willis C, Staatz CE, Tett SE. Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. Ther Drug Monit 2003; 25: 158–66PubMedCrossRef
218.
Prasad TN, Stiff DD, Subbotina N, et al. FK 506 (tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. Res Commun Chem Pathol Pharmacol 1994; 84(1): 35–46PubMed
219.
Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41(3): 187–90PubMedCrossRef
220.
Iwasaki K, Matsuda H, Nagase K, et al. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993; 82(2): 209–16PubMed
221.
Matsuda H, Iwasaki K, Shiraga T, et al. Interactions of FK506 (tacrolimus) with clinically important drugs. Res Commun Mol Pathol Pharmacol 1996; 91(1): 57–64PubMed
222.
Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997; 16(4): 267–78PubMedCrossRef
223.
Rui X, Flowers J, Warty V, et al. Drug interactions with FK506 [abstract]. Pharm Res 1992; 9(10): S314
224.
Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54(6): 925–75PubMedCrossRef
225.
226.
European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423–8CrossRef
227.
The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110–5CrossRef
228.
Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64(3): 436–43PubMedCrossRef
229.
Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63(7): 977–83PubMedCrossRef
230.
Williams R, Neuhaus P, Bismuth H, et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. Transpl Int 1996; 9 Suppl. 1: S144–50PubMedCrossRef
231.
Mor E, Yussim A, Chodoff L, et al. New immunosuppressive agents for maintenance therapy in organ transplantation: focus on adverse effects. BioDrugs 1997; 16(4): 242–57
232.
Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant 1999; 13(3): 209–20PubMedCrossRef
233.
Fung JJ, Todo S, Tzakis A, et al. Conversion of liver allograft recipients from cyclosporine to FK 506- based immunosuppression: benefits and pitfalls. Transplant Proc 1991; 23(1 Pt 1): 14–21PubMed
234.
Jain A, McCauley J, Kashyap R. Incidence of end-stage renal failure amongst long-term survival of primary liver transplant recipients under tacrolimus: adults and children [abstract]. Transplantation 1998; 65: S24CrossRef
235.
Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immuosuppressive agent. Am J Health Syst Pharm 1995; 52(14): 1521–35PubMed
236.
Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc 1991; 23(6): 3175–8PubMed
237.
Chang CWJ. Neurological complications of critical illness and transplantation. Curr Opin Crit Care 1999; 5(2): 112–8CrossRef
238.
Mueller AR, Platz KP, Christe W, et al. Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. Transplant Proc 1994; 26(6): 3131–2PubMed
239.
Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus: the role of immunosuppression. Drug Saf 1997; 16(4): 242–57PubMedCrossRef
240.
Bonomini V, For the Italian-Spanish Tacrolimus Study Group. Low rejection rates with tacrolimus-based dual and triple regimens following renal transplantation [abstract]. J Am Soc Nephrol 1999; 10: 720A
241.
Peters DH, Fitton A, Plosker GL, et al. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46(4): 746–94PubMedCrossRef
242.
Abouljoud MS, Levy MF, Klintmalm GB. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter trial. US Multicenter Study Group. Transplant Proc 1995; 27(1): 1121–3PubMed
243.
Burke GW, Ciancio G, Alejandro R, et al. Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. Transplant Proc 1998; 30(2): 513–4PubMedCrossRef
244.
Canzanello VJ, Schwartz L, Taler SJ, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997; 3(1): 1–9PubMedCrossRef
245.
Claesson K, Mayer AD, Squifflet JP, et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. Transplant Proc 1998; 30(4): 1292–4PubMedCrossRef
246.
Friemann S, Feuring E, Padberg W, et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc 1998; 30(4): 1240–2PubMedCrossRef
247.
Guckelberger O, Bechstein WO, Neuhaus R, et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997; 11(1): 60–5PubMed
248.
McCune TR, Thacker LR, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998; 65(1): 87–92PubMedCrossRef
249.
Penson MG, Winter WE, Fricker FJ, et al. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. J Heart Lung Transplant 1999; 18(7): 707–13PubMedCrossRef
250.
Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18(4): 336–45PubMedCrossRef
251.
Varghese Z, Fernando RL, Turakhia G, et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus- treated renal transplant patients. Transplant Proc 1998; 30(5): 2043–6PubMedCrossRef
252.
Fagiuoli S, Gasbarrini A, Azzarone A, et al. FK 506: a new immunosuppressive agent for organ transplantation: pharmacology, mechanism of action and clinical applications. Ital J Gastroenterol 1992; 24(6): 355–60PubMed
253.
Li PKT, Nicholls MG, Lai KN. The complications of newer transplant antirejection drugs: treatment with cyclosporin-A, OKT-3 and FK506. Adverse Drug React Acute Poisoning Rev 1990; 9: 123–55PubMed
254.
McCauley J, Fung J, Jain A, et al. The effects of FK 506 on renal function after liver transplantation. Transplant Proc 1990; 22(1): 17–20PubMed
255.
Niederstadt C, Steinhoff J, Erbsloh-Moller B, et al. Effect of FK506 on magnesium homeostasis after renal transplantation. Transplant Proc 1997; 29(7): 3161–2PubMedCrossRef
256.
Mayer AD. Four-year follow-up of the European Tacrolimus Multicenter Renal Study. Transplant Proc 1999; 31(7A): 27–8SCrossRef
257.
Tzakis AG, Fung JJ, Todo S, et al. Use of FK 506 in pediatric patients. Transplant Proc 1991; 23(1 Pt 2): 924–7PubMed
258.
Tzakis AG, Reyes J, Todo S, et al. Two-year experience with FK 506 in pediatric patients. Transplant Proc 1993; 25(1 Pt 1): 619–21PubMed
259.
Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64(10): 1438–42PubMedCrossRef
260.
Shapiro R, Scantlebury VP, Jordan ML, et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999; 67(2): 299–303PubMedCrossRef
261.
Jain A, Reyes J, Kashyap R, et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc 1998; 30(4): 1403–4PubMedCrossRef
262.
Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 1996; 61(2): 247–52PubMedCrossRef
263.
So S, The US Multicentre FK506 Liver Study Group. Post-transplant lymphoproliferative disease (PTLD) in tacrolimus-treated liver transplant patients [abstract 207]. Proceedings of the 15th Annual Meeting of the American Society of Transplant Physicians; 1996 May 26–30; Dallas: 136
264.
Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation: interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62(3): 370–5PubMedCrossRef
265.
Paolillo JA, Wagner K, Boyle GE, et al. Post-transplant diabetes mellitus in paediatric thoracic organ recipients receiving tacrolimus-based immunosuppression [abstract]. Transplantation 1999; 67(7): S230CrossRef
266.
Moxey-Mims MM, Kay C, Light JA, et al. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506). Transplantation 1998; 65(5): 617–9PubMedCrossRef
267.
Backman L, Levy MF, Klintmalm G. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. Transplant Proc 1995; 27(1): 1124
268.
Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients: correlation with clinical events and side effects. Transplantation 1994; 57(4): 519–25PubMed
269.
Bottiger Y, Brattstrom C, Tyden G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999; 48(3): 445–8PubMedCrossRef
270.
Jain AB, Todo S, Fung JJ, et al. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. Transplant Proc 1991; 23(6): 3023–5PubMed
271.
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. Transplant Proc 1991; 23(6): 3085–8
272.
Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62(7): 920–6PubMedCrossRef
273.
Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62(7): 900–5PubMedCrossRef
274.
Przepiorka D, Nash RA, Wingard JR, et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 1999; 5(2): 94–7PubMedCrossRef
275.
Sandborn WJ, Lawson GM, Cody TJ, et al. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology 1995; 21(1): 70–6PubMed
276.
Schwartz M, Holst B, Facklam D, et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. Transplant Proc 1995; 27(1): 1107
277.
Takahara S, Kokado Y, Kameoka H, et al. Monitoring of FK 506 blood levels in kidney transplant recipients. Transplant Proc 1994; 26(4): 2106–8PubMed
278.
Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31(1–2): 296–8PubMedCrossRef
279.
Winkler M, Pichlmayr R, Neuhaus P, et al. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. Transpl Int 1994; 7 Suppl. 1: S58–63PubMedCrossRef
280.
Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf 1995; 12(5): 348–57PubMedCrossRef
281.
Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001; 41(5): 542–51PubMedCrossRef
282.
Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001; 16(9): 1905–9PubMedCrossRef
283.
Winkler M, Wonigeit K, Undre N, et al. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. Transplant Proc 1995; 27(1): 822–5PubMed
284.
Ringe B, Braun F, Lorf T, et al. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. Transplant Proc 1998; 30(4): 1415–6PubMedCrossRef
285.
Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996; 30(2): 107–40PubMedCrossRef
286.
Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001; 34(1): 9–16PubMedCrossRef
287.
Shaw LM, Holt DW, Keown P, et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999; 21(10): 1632–52PubMedCrossRef
288.
Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24(3): 330–50PubMedCrossRef
289.
Oellerich M, Armstrong VW, Schutz E, et al. Therapeutic drug monitoring of cyclosporine and tacrolimus: update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998; 31(5): 309–16PubMedCrossRef
290.
Alak AM, Moy S, Cook M, et al. An HPLC/MS/MS assay for tacrolimus in patient blood samples: correlation with results of an ELISA assay. J Pharm Biomed Anal 1997; 16(1): 7–13PubMedCrossRef
291.
Christians U, Jacobsen W, Serkova N, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl 2000; 748(1): 41–53PubMedCrossRef
292.
Deters M, Kirchner G, Resch K, et al. Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS). Clin Chem Lab Med 2002; 40(3): 285–92PubMedCrossRef
293.
Keevil BG, McCann SJ, Cooper DP, et al. Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatographytandem mass spectrometry. Ann Clin Biochem 2002; 39 (Pt 5): 487–92PubMedCrossRef
294.
Lensmeyer GL, Poquette MA. Therapeutic monitoring of tacrolimus concentrations in blood: semi-automated extraction and liquid chromatography-electrospray ionization mass spectrometry. Ther Drug Monit 2001; 23(3): 239–49PubMedCrossRef
295.
Salm P, Taylor PJ, Clark A, et al. High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants. Ther Drug Monit 1997; 19(6): 694–700PubMedCrossRef
296.
Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem 2002; 48(6 Pt 1): 955–8PubMed
297.
Taylor PJ, Salm P, Lynch SV, et al. Simultaneous quantification of tacrolimus and sirolimus, in human blood, by highperformance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2000; 22(5): 608–12PubMedCrossRef
298.
Volosov A, Napoli KL, Soldin SJ. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography: tandem mass-spectrometry. Clin Biochem 2001; 34(4): 285–90PubMedCrossRef
299.
Zhang Q, Simpson J, Aboleneen HI. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry. Ther Drug Monit 1997; 19(4): 470–6PubMedCrossRef
300.
Braun F, Peters B, Schutz E, et al. Therapeutic drug monitoring of tacrolimus early after liver transplantation. Transplant Proc 2002; 34(5): 1538–9PubMedCrossRef
301.
Jorgensen K, Povlsen J, Maden S, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002; 17: 1487–90PubMedCrossRef
302.
Cantarovich M, Fridell J, Barkun J, et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proc 1998; 30(4): 1460–1PubMedCrossRef
303.
Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000; 35: 660–6PubMedCrossRef
304.
Pisitkun T, Eiam-Ong S, Chusil S, et al. The roles of C4 and AUC0–4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc 2002; 34: 3173–5PubMedCrossRef
305.
Ku YM, Min DI. An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit 1998; 20(2): 219–23PubMedCrossRef
306.
Stolk LM, Van Duijnhoven EM, Christiaans MH, et al. Evaluation of prediction of tacrolimus area under the curve by trough concentrations [abstract]. Br J Clin Pharmacol 2002; 53(5): 554CrossRef
307.
Jorgensen KA, Povlsen JV, Poulsen JH. Optimal time for determination of blood tacrolimus level. Transplant Proc 2001; 33(7–8): 3164–5PubMedCrossRef
308.
Uchida K, Tominaga Y, Haba T, et al. Usefulness of monitoring of AUC(0–4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. Transplant Proc 2002; 34(5): 1736–7PubMedCrossRef
309.
Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000; 12(5): 557–62PubMedCrossRef
310.
Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17(6): 584–91PubMedCrossRef
311.
Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996; 10(1 Pt 2): 118–23PubMed
312.
Halloran PF, Kung L, Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc 1998; 30(5): 2167–70PubMedCrossRef
313.
Yatscoff RW, Aspeslet LJ. The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Ther Drug Monit 1998; 20(5): 459–63PubMedCrossRef
314.
Koefoed-Nielsen P, Jorgensen K. Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. Transplant Proc 2002; 34(5): 1743–4PubMedCrossRef
315.
Koefoed-Nielsen PB, Gesualdo MB, Poulsen JH, et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Am J Transplant 2002; 2(2): 173–8PubMedCrossRef
316.
Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation 2000; 70(2): 327–35PubMedCrossRef
317.
Dumont RJ, Ensom MH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet 2000; 38(5): 427–47PubMedCrossRef
318.
Andersson U, Hallden G, Persson U, et al. Enumeration of IFN-gamma-producing cells by flow cytometry: comparison with fluorescence microscopy. J Immunol Methods 1988; 112(1): 139–42PubMedCrossRef
319.
Jung T, Schauer U, Heusser C, et al. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159(1-2): 197–207PubMedCrossRef
320.
Assenmacher M, Schmitz J, Radbruch A. Flow cytometric determination of cytokines in activated murine T helper lymphocytes: expression of interleukin-10 in interferon-gamma and in interleukin-4-expressing cells. Eur J Immunol 1994; 24(5): 1097–101PubMedCrossRef
321.
Picker LJ, Singh MK, Zdraveski Z, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995; 86(4): 1408–19PubMed
322.
Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods 1995; 188(1): 117–28PubMedCrossRef
323.
Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs tacrolimus) in stable renal allograft recipients. Clin Transplant 1999; 13(5): 400–9PubMedCrossRef
324.
Sewell WA, North ME, Webster AD, et al. Determination of intracellular cytokines by flow-cytometry following whole-blood culture. J Immunol Methods 1997; 209(1): 67–74PubMedCrossRef
325.
van den Berg AP, Twilhaar WN, van Son WJ, et al. Quantification of immunosuppression by flow cytometric measurement of intracellular cytokine synthesis. Transpl Int 1998; 11 Suppl. 1: S318–21PubMed
326.
Ahmed M, Venkataraman R, Logar AJ, et al. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(−) and CD8(+) peripheral blood T cells. Ther Drug Monit 2001; 23(4): 354–62PubMedCrossRef
327.
van den Berg AP, van Son WJ, Haagsma EB, et al. Prediction of the inhibition of IL-2 production by calcineurin inhibitors. Transplant Proc 2001; 33(1–2): 1076–7PubMedCrossRef
328.
Ahmed M, Venkataramanan R, Logar AJ, et al. Quantitation of immunosuppression by FK506 using flow cytometric analysis of IL-2 and INF-gamma inhibition in peripheral blood cells [abstract]. Transplantation 2000; 69: S393CrossRef
329.
Klupp J, Dambrin C, Regieli J, et al. New approach in drug development: whole blood pharmacodynamic assays reflect biological activities of tacrolimus. Transplant Proc 2001; 33(3): 2172PubMedCrossRef
Metadata
Title
Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
Authors
Dr Christine E. Staatz
Susan E. Tett
Publication date
01-08-2004
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 10/2004
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200443100-00001